These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3893693)

  • 1. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
    Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
    Camaggi CM; Strocchi E; Martoni A; Angelelli B; Comparsi R; Pannuti F
    Drugs Exp Clin Res; 1985; 11(4):285-94. PubMed ID: 3869807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer.
    Peterson C; Gunvén P; Theve NO
    Cancer Treat Rep; 1986 Aug; 70(8):947-52. PubMed ID: 3460699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics and metabolism of epirubicin in cancer patients in an advanced stage].
    Strocchi E; Camaggi CM; Pannuti F
    G Ital Chemioter; 1985; 32(1):13-20. PubMed ID: 3868635
    [No Abstract]   [Full Text] [Related]  

  • 6. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
    Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
    Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of epirubicin in cancer patients].
    Ohno T; Shimoyama T; Kimura K; Yamada H
    Gan To Kagaku Ryoho; 1986 May; 13(5):1881-6. PubMed ID: 3458430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study.
    Gebbia V; Blasi L; Borsellino N; Caruso M; Leonardi V; Agostara B; Valenza R
    Anticancer Res; 2003; 23(1B):765-71. PubMed ID: 12680181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.
    Camaggi CM; Strocchi E; Tamassia V; Martoni A; Giovannini M; Lafelice G; Canova N; Marraro D; Martini A; Pannuti F
    Cancer Treat Rep; 1982 Oct; 66(10):1819-24. PubMed ID: 6957263
    [No Abstract]   [Full Text] [Related]  

  • 11. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
    Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer.
    O'Shaughnessy JA; Fisherman JS; Cowan KH
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):19-23. PubMed ID: 7939757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Lisboa BW; Untch M; Kühnle H; Jänicke F; Meerpohl HG; Lindner C; Konecny G; Hecker D; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S13-6. PubMed ID: 9071334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
    Ries F; Duhem C; Kleiber K; Dicato M
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
    Buzdar AU; Holmes FA; Hortobagyi GN
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration.
    Strocchi E; Camaggi CM; Rossi AP; Angelelli B; Comparsi R; Franchini A; Del Prete P; Cola B; Pannuti F
    Drugs Exp Clin Res; 1985; 11(4):295-301. PubMed ID: 3013561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
    Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
    J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer.
    Hortobagyi GN; Holmes FA
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S4-7. PubMed ID: 9071332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.